COMMUNIQUÉS West-GlobeNewswire

Bio Usawa Takes Major Step Toward Building a Self-Sustaining Biotechnology Ecosystem in Africa
08/10/2026
The establishment of Botswana subsidiary strengthens regional capacity and expands access to affordable biologics SAN FRANCISCO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology today announced the launch of [...]
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
08/10/2026
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176 ) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx [...]
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
08/10/2026
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod [...]
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
08/10/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Regulated information – inside information: Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range
08/10/2026
Regulated information – inside information Nazareth-De Pinte (Belgium)/Rotterdam (The Netherlands), 8 October 2026 – 7:00 AM CET Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and [...]
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance
08/10/2026
Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial [...]
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
07/10/2026
Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin HIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv [...]
Lifecore Biomedical to Participate at Upcoming Industry Conferences
07/10/2026
CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
07/10/2026
WILMINGTON, Del., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the [...]
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
07/10/2026
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“ [...]
Leo International Precision Health AG: Mr. Leo Wang, Disposal
07/10/2026
Leo International Precision Health AG: Mr. Leo Wang, Disposal Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them, 07. Oct 2026 [...]
Optogenetic therapy is safe and allows blind people to detect objects
07/10/2026
Five years after a landmark result in one patient, the first treated cohort shows that optogenetic vision restoration works beyond a single case. Basel, 7 October 2026 - An international research team has reported new [...]
Neo Dental Beverly Hills Introduces Neo-Essentialism: A Modern Approach to Clinical Decision-Making and a New Way to Think About Dentistry’s Future
08/10/2026
As dentistry moves toward regeneration, artificial intelligence, and biologic preservation, the Beverly Hills dentist behind the concept is asking whether progress may increasingly be defined by what clinicians can [...]
ALK upgrades its full-year outlook on strong tablet sales
07/10/2026
Inside Information ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong growth momentum in tablet sales across regions. Revenue is now [...]
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
07/10/2026
Company announcement – No. 54 / 2026 Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes Petrelintide achieved up [...]
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
07/10/2026
SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for [...]
Embark Behavioral Health Relocating Rockville Outpatient Clinic to Germantown – Providing Expanded Room for Care
07/10/2026
Embark Behavioral Health announced today that its intensive outpatient clinic in Rockville will relocate to a larger space in Germantown, with the first day of programming at the new location scheduled for Monday, Nov. [...]
Valneva fait un point sur l’utilisation d’IXCHIQ® au Royaume-Uni
07/10/2026
Lyon (France), le 7 octobre 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui qu’à la suite d’une nouvelle évaluation du rapport bénéfice-risque d’IXCHIQ [...]
Valneva Provides Update on IXCHIQ® in the United Kingdom
07/10/2026
Lyon (France), October 07, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ ® for travelers by the United [...]

Pages